Top Story

Morning Read: How to squeeze every ounce of information out of JP Morgan 2016

Also, BioAtla closes a major round, Pfizer jacks up it’s U.S. drug prices and bad advice on forming your digital health startup.

Jamie Dimon JP Morgan healthcare

TOP STORIES

You may have heard there’s a little healthcare conference called JP Morgan 2016 happening this week. From now through Thursday, MedCity News will send out a separate newsletter with all of our daily JP Morgan Healthcare Conference coverage. Anyone who subscribes to our daily e-newsletter will get it and it will include some stories our typical morning e-mail will not. So sign up here today (our JPM e-mail will be sent around 9 a.m. Eastern).

LIFE SCIENCES

Shire-Baxalta: Done. – Boston Globe

Sanofi has inked a five-year, $750 million collaboration with Warp Drive Bio to develop oncogenes including RAS, which has one of the highest mutation rates in cancer, and new antibiotics targeting Gram-negative bacteria. The money is as much of a game-changer as are the terms, which provides Warp Drive more freedom to pursue major partnership with other partners. – Pharma Times, FierceBiotech

Novartis has thrown in with Surface Oncology, providing $170 million to develop its cancer immunotherapy pipeline. – FierceBiotech

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

Sneaky ole Pfizer, which won’t have to bother with those American tax rates much longer, went ahead and raised U.S. prices on more than 100 drugs – including a nearly 10 percent hike for Lyrica. – Reuters

Spain’s Aelix Therapeutics, which is developing immunotherapies against HIV infection, raised $12.7 million lead by Ysios Capital and Johnson & Johnson Development Corp., among others. – PE Hub

BioAtla just landed $45 million from the Global BIO Impact Fund to develop a series of Conditionally Active Biologic antibody therapeutics. – PRNewswire

PAYERS-PROVIDERS

Russian investigators have opened a criminal probe in the case of a patient who died after he was punched in the head by a doctor. This is the video:

The Associated Press

TECHNOLOGY

Here’s a massive and handy list of everything Google is working on in 2016 (there’s healthcare in there). – Ars Technica

Check out the HISTalk reader survey. I enjoyed the feedback on reader suggestions. – HISTalk

Remember, when you are building a healthcare company you should not have a doctor on your team. – VentureBeat

POLITICS

Will the ghosts of the past haunt the NIH’s attempts to go big on precision medicine? – STAT

A LITTLE BIT EXTRA

In case you missed it: “The Revenant” won best movie drama while that health IT-hating “Mr. Robot” won for best TV drama at the Golden Globes. All your Golden Globes details here. – New York Times

Photo: Getty Images

Topics